Evaluation of Reaction of Primate Brain to Grafted PC12 Cells
Open Access
- 1 July 1999
- journal article
- research article
- Published by SAGE Publications in Cell Transplantation
- Vol. 8 (4) , 427-430
- https://doi.org/10.1177/096368979900800413
Abstract
Intrastriatal implantation of polymer-encapsulated PC12 cells, which constitute a dopaminergic cell line derived from rat pheochromocytoma, has proved useful for ameliorating parkinsonian symptoms in several kinds of animals. In considering the clinical application of this technique, we should make sure that PC12 cells are rejected completely by the host immune system in case the capsule breaks. In the present study, unencapsulated PC12 cells were injected into the brain of Japanese monkeys (Macaca fuscata). Histological [hematoxylin-eosin (H&E), Nissl] and immunocytochemical [tyrosine hydroxylase (TH), and glial fibrillary acidic protein (GFAP)] analyses were performed 1, 2, 4, and 8 weeks after transplantation. Also, encapsulated PC12 cells were transplanted into the brain of another group of Japanese monkeys to investigate the host reaction to the capsule and to confirm that the encapsulated PC12 cells continue to survive in the host brain. H&E and GFAP staining were performed 2, 4, and 8 weeks after transplantation. L-DOPA and dopamine release from the explanted capsules was measured by high performance liquid chromatography. Magnetic resonance imaging was performed in both unencapsulated and encapsulated PC12 cell grafted groups. Although the xenografted unencapsulated cells formed a small cluster at 1 and 2 weeks after implantation, very few and no viable PC12 cells remained at 4 and 8 weeks, respectively. The reaction of the host towards the xenograft gradually decreased. Encapsulated PC12 cells retrieved from the host brain were found to release L-DOPA and dopamine continuously even 8 weeks after implantation. The host reaction to the PC12-loaded capsule was much weaker than that to the unencapsulated PC12 cells, and decreased with time. These results indicate that encapsulated PC12 cell transplantation is an effective and safe strategy for the treatment of Parkinson's disease.Keywords
This publication has 12 references indexed in Scilit:
- Polymer-Encapsulated PC-12 Cells Demonstrate High-Affinity Uptake of Dopamine in Vitro and 18F-DOPA Uptake and Metabolism after Intracerebral Implantation in Nonhuman PrimatesCell Transplantation, 1997
- Somatic Delivery of Catecholamines in the Striatum Attenuate Parkinsonian Symptoms and Widen the Therapeutic Window of Oral Sinemet in RatsExperimental Neurology, 1997
- Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerveJournal of Neurosurgery, 1996
- Histological Analysis of Microencapsulated Dopamine-Secreting Cells in Agarose/Poly(styrene sulfonic acid) Mixed Gel Xenotransplanted into the BrainExperimental Neurology, 1996
- Two-year Follow-up Study of a Patient with Parkinson's Disease and Severe Motor Fluctuations Treated by Co-grafts of Adrenal Medulla and Peripheral Nerve into Bilateral Caudate NucleiNeurosurgery, 1995
- Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptomsExperimental Neurology, 1995
- Encapsulated PC 12 Cell Transplants into Hemiparkinsonian Monkeys: A Behavioral, Neuroanatomical, and Neurochemical AnalysisCell Transplantation, 1995
- Autologous Transplantation of the Cervical Sympathetic Ganglion into the Parkinsonian BrainNeurosurgery, 1994
- Functional Recovery in Hemiparkinsonian Primates Transplanted with Polymer-Encapsulated PC12 CellsExperimental Neurology, 1994
- Polymer-Encapsulated PC12 Cells Promote Recovery of Motor Function in Aged RatsExperimental Neurology, 1993